ATE477272T1 - Verwendung von stefin a als gerüstprotein - Google Patents

Verwendung von stefin a als gerüstprotein

Info

Publication number
ATE477272T1
ATE477272T1 AT06744166T AT06744166T ATE477272T1 AT E477272 T1 ATE477272 T1 AT E477272T1 AT 06744166 T AT06744166 T AT 06744166T AT 06744166 T AT06744166 T AT 06744166T AT E477272 T1 ATE477272 T1 AT E477272T1
Authority
AT
Austria
Prior art keywords
stefin
scaffold
mutations
relates
leu73
Prior art date
Application number
AT06744166T
Other languages
English (en)
Inventor
Robbie Woodman
Johannes Yeh
Sophie Laurenson
Ferrigno Paul Ko
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511873A external-priority patent/GB0511873D0/en
Priority claimed from GB0608836A external-priority patent/GB0608836D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE477272T1 publication Critical patent/ATE477272T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06744166T 2005-06-10 2006-06-08 Verwendung von stefin a als gerüstprotein ATE477272T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511873A GB0511873D0 (en) 2005-06-10 2005-06-10 Scaffold
GB0608836A GB0608836D0 (en) 2006-05-04 2006-05-04 Scaffold
PCT/GB2006/002115 WO2006131749A2 (en) 2005-06-10 2006-06-08 Scaffold

Publications (1)

Publication Number Publication Date
ATE477272T1 true ATE477272T1 (de) 2010-08-15

Family

ID=37314237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744166T ATE477272T1 (de) 2005-06-10 2006-06-08 Verwendung von stefin a als gerüstprotein

Country Status (9)

Country Link
US (2) US8063019B2 (de)
EP (1) EP1904529B1 (de)
JP (1) JP4989638B2 (de)
AT (1) ATE477272T1 (de)
AU (1) AU2006256530B2 (de)
CA (1) CA2610976C (de)
DE (1) DE602006016133D1 (de)
DK (1) DK1904529T3 (de)
WO (1) WO2006131749A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006016133D1 (de) * 2005-06-10 2010-09-23 Medical Res Council London Verwendung von stefin a als gerüstprotein
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
KR102349259B1 (ko) 2017-01-04 2022-01-07 엠쥐아이 테크 컴퍼니 엘티디. 친화성 시약을 이용한 핵산 시퀀싱
JP7273721B2 (ja) 2017-05-19 2023-05-15 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 対象の喫煙ステータスを区別するための診断テスト
GB201710973D0 (en) * 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP4045536A4 (de) * 2019-10-16 2023-11-01 Lg Chem, Ltd. Neonatale fc-rezeptor bindende affimere
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2023182945A2 (en) * 2022-03-24 2023-09-28 Agency For Science, Technology And Research Engineering peptides using peptide epitope linker evolution
WO2024141788A1 (en) * 2022-12-29 2024-07-04 Affyxell Therapeutics Co., Ltd. Genetically modified stem cells expressing exogenous binding agents and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016173A2 (en) * 1994-11-21 1996-05-30 The University Of Leeds Modified proteinase inhibitors
EA003637B1 (ru) * 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней
WO2005047511A2 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
DE602006016133D1 (de) * 2005-06-10 2010-09-23 Medical Res Council London Verwendung von stefin a als gerüstprotein

Also Published As

Publication number Publication date
EP1904529A2 (de) 2008-04-02
US20120190819A1 (en) 2012-07-26
AU2006256530B2 (en) 2012-12-20
DK1904529T3 (da) 2010-11-15
CA2610976A1 (en) 2006-12-14
AU2006256530A1 (en) 2006-12-14
EP1904529B1 (de) 2010-08-11
WO2006131749A3 (en) 2007-05-18
US8481491B2 (en) 2013-07-09
JP2008541776A (ja) 2008-11-27
DE602006016133D1 (de) 2010-09-23
JP4989638B2 (ja) 2012-08-01
US8063019B2 (en) 2011-11-22
US20080207509A1 (en) 2008-08-28
WO2006131749A2 (en) 2006-12-14
CA2610976C (en) 2020-11-24

Similar Documents

Publication Publication Date Title
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
ATE540111T1 (de) Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
ATE309536T1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DE69820885D1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
Claeys et al. Multiple gene duplication in the evolution of plasminogen. Five regions of sequence homology with the two internally homologous structures in prothrombin
DK1194560T3 (da) Antigene Neisseria-peptider
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
DE60335726D1 (de) Chromoprotein und fluoroproteine
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
IL173954A0 (en) Libraries of recombinant chimeric proteins and methods of generating the same
ATE323763T1 (de) Dna & protein bindende miniatur proteine
DE60028248D1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
DK1913020T3 (da) Immunogene konstrukter
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
DK2186898T3 (da) Blomstrings-induktion
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
ATE369377T1 (de) Verfahren zum spalten von proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1904529

Country of ref document: EP